These studies allowed to identifying the target of 180 monoclonal Igs; among those, 14 were from RRMM patients (Supplementary Table S1, Supplementary Figure S1), 46 were from NDMM patients and 120 were from MGUS/SM patients [6,9,10]. Here, CUBN is linked to systemic mastocytosis.